
Heli Malm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/472169/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Paroxetine and congenital malformations: Meta-Analysis and consideration of potential confounding factors. Clinical Therapeutics, 2007, 29, 918-926.	2.5	214
2	Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies. Obstetrics and Gynecology, 2011, 118, 111-120.	2.4	183
3	Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy. Obstetrics and Gynecology, 2005, 106, 1289-1296.	2.4	180
4	Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 359-366.	0.5	170
5	Evaluation of the Risk of Congenital Cardiovascular Defects Associated With Use of Paroxetine During Pregnancy. American Journal of Psychiatry, 2008, 165, 749-752.	7.2	164
6	Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ, The, 2015, 350, h1798-h1798.	6.0	152
7	Pregnancy outcome after TNFâ€i± inhibitor therapy during the first trimester: a prospective multicentre cohort study. British Journal of Clinical Pharmacology, 2015, 80, 727-739.	2.4	125
8	Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring. JAMA Psychiatry, 2016, 73, 1163.	11.0	117
9	Pregnancy Complications Following Prenatal Exposure to SSRIs or Maternal Psychiatric Disorders: Results From Population-Based National Register Data. American Journal of Psychiatry, 2015, 172, 1224-1232.	7.2	106
10	Prescription drugs during pregnancy and lactation—a Finnish register-based study. European Journal of Clinical Pharmacology, 2003, 59, 127-133.	1.9	74
11	Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reproductive Toxicology, 2010, 30, 249-260.	2.9	71
12	Effects of Maternal Epilepsy and Antiepileptic Drug Use during Pregnancy on Perinatal Health in Offspring: Nationwide, Retrospective Cohort Study in Finland. Drug Safety, 2013, 36, 359-369.	3.2	52
13	Prescription of Hazardous Drugs During Pregnancy. Drug Safety, 2004, 27, 899-908.	3.2	50
14	New Insights into How Serotonin Selective Reuptake Inhibitors Shape the Developing Brain. Birth Defects Research, 2017, 109, 924-932.	1.5	47
15	Nationwide registerâ€based surveillance system on drugs and pregnancy in Finland 1996–2006. Pharmacoepidemiology and Drug Safety, 2011, 20, 729-738.	1.9	39
16	Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability. Orphanet Journal of Rare Diseases, 2019, 14, 180.	2.7	33
17	Pregnancy Outcome Following Maternal Exposure to Mirtazapine. Journal of Clinical Psychopharmacology, 2015, 35, 250-259.	1.4	32
18	Specialized Service Use for Psychiatric and Neurodevelopmental Disorders by Age 14 in Finland. Psychiatric Services, 2014, 65, 367-373.	2.0	26

Heli Malm

#	Article	IF	CITATIONS
19	Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. Reproductive Toxicology, 2015, 57, 204-206.	2.9	25
20	Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome. Therapeutic Drug Monitoring, 2012, 34, 607-614.	2.0	23
21	Second-generation antipsychotics and pregnancy complications. European Journal of Clinical Pharmacology, 2020, 76, 107-115.	1.9	22
22	Infant and childhood neurodevelopmental outcomes following prenatal exposure to selective serotonin reuptake inhibitors: overview and design of a Finnish Register-Based Study (FinESSI). BMC Psychiatry, 2012, 12, 217.	2.6	19
23	Second-generation antipsychotic use during pregnancy and risk of congenital malformations. European Journal of Clinical Pharmacology, 2021, 77, 1737-1745.	1.9	16
24	Genetic variants within the serotonin transporter associated with familial risk for major depression. Psychiatry Research, 2015, 228, 170-173.	3.3	13
25	Placental transporterâ€mediated drug interactions and offspring congenital anomalies. British Journal of Clinical Pharmacology, 2020, 86, 868-879.	2.4	9
26	Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies. Obstetrics and Gynecology, 2011, 118, 1420-1421.	2.4	1
27	Dr. Malm etÂal. reply:. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 726-727.	0.5	Ο
28	Serotonin Reuptake Inhibitor Use During Pregnancy—Reply. JAMA Psychiatry, 2017, 74, 539.	11.0	0